MarketLens
Sign Up

Eli Lilly's $2.8 Billion Psychedelic Bet: High Stakes in a Nascent Market

4 months ago
SHARE THIS ON:

Eli Lilly's $2.8 Billion Psychedelic Bet: High Stakes in a Nascent Market

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

News•2 months ago

First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.

Definium Therapeutics reported positive late-stage trial data for DT120, its experimental medical LSD-based drug, advancing the case for psychedelic medicine as a Wall Street theme.
Stock News•2 months ago

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma's psychedelic platform, spanning MDD and GAD, approaches a phase III catalyst for HLP003. Early data suggest efficacy, but small trials limit validation. Positive results could reduce its...
Stock News•4 months ago

Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion

Eli Lilly agreed to buy AtaiBeckley Inc. for up to $3.8 billion, highlighting large drugmaker interest in psychedelic medicine.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

An Nvidia engineer says he's quitting because Jensen Huang was ousted: 'So disappointing'

Stock News•2 hours ago

Is bad news for Jensen Huang also bad news for the AI industry?

Stock News•2 hours ago

Amazon loses 40 Leo satellites in ULA Vulcan launch failure — a new setback for its Starlink rival

Stock News•2 hours ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages NVIDIA Corporation Investors with Losses in Excess of $500k to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NVDA

Stock News•3 hours ago

Nvidia CEO Jensen Huang Resigns as Stock Tanks. Here Are the Next Steps for Investors.